Home / Market News / $AXSM
benzinga Corporate Catalyst Impact 75/100 ● negative

Axsome Therapeutics shares are trading lower after Deutsche Bank lowered its price target on the stock from $280 to $267.

Sep 29, 2026, 7:43 PM UTC · Primary ticker $AXSM

Axsome Therapeutics shares are down following a price target reduction by Deutsche Bank, indicating a potential re-evaluation of the company's future growth prospects by a major financial institution. This downgrade suggests a more cautious outlook on the stock's valuation, likely influencing investor sentiment negatively. The immediate impact is a decline in share price, reflecting the market's reaction to the revised analyst expectations.

The headline indicates a significant negative corporate catalyst for Axsome Therapeutics. Deutsche Bank's decision to lower its price target from $280 to $267, while still a high target, signals a reduction in perceived upside potential or an increase in perceived risk. This can lead to a sell-off as investors adjust their valuations and potentially reallocate capital. Key risks include further analyst downgrades, negative clinical trial news, or increased competition. The biotechnology sector is particularly sensitive to analyst ratings and clinical developments, making such a downgrade impactful. Trading implications involve potential short-term downward pressure on AXSM shares and increased volatility as the market digests this news.

$AXSM negative Price target lowered by Deutsche Bank
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.